C12N 2760/20041
Use of virus, viral particle or viral elements as a vector
C12N2760/20041 (Use of virus, viral particle or viral elements as a vector) appears on 24 US grants and 45 published applications in this corpus.
Search patents in C12N- Granted patents
- 24
- Published applications
- 45
- Assignees
- 31
- Inventors
- 69
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 1 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 1 | 4 |
| 2015 | 0 | 2 |
| 2016 | 2 | 1 |
| 2017 | 1 | 1 |
| 2018 | 1 | 1 |
| 2019 | 0 | 4 |
| 2020 | 2 | 4 |
| 2021 | 2 | 6 |
| 2022 | 1 | 3 |
| 2023 | 5 | 6 |
| 2024 | 2 | 5 |
| 2025 | 3 | 2 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/20043Viral genome or elements thereof as genetic vectorIndexing code17
- C12N 2760/20042Virus or viral particle as vehicleIndexing code3
- C12N 2760/20045Special targeting system for viral vectorsIndexing code2
- C12N 2760/20044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
Recent patents
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Recombinant rhabdovirus encoding for CCL2128 Oct 2025US 12,453,749 B2Boehringer Ingelheim International GmbH
- Recombinant oncolytic virus8 Jul 2025US 12,351,812 B2Georgia State University Research Foundation, Inc.
- Multivalent vaccines for rabies virus and coronaviruses8 Apr 2025US 12,269,155 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Recombinant rhabdovirus encoding for a CD80 extracellular domain Fc-fusion protein24 Dec 2024US 12,171,795 B2Boehringer Ingelheim International GmbH
- Novel vsv virus formulations7 May 2026US 2026/0124288 A1Emergent Product Development Gaithersburg Inc.
- Neddylation-activating enzyme inhibitors as viral sensitizers and uses thereof15 Jan 2026US 2026/0015592 A1Ottawa Hospital Research Institute
- Modified rhabdovirus glycoproteins and uses thereof6 Nov 2025US 2025/0339384 A1Regeneron Pharmaceuticals, Inc.
- Recombinant rhabdovirus encoding for a CD80 extracellular domain Fc-fusion protein20 Feb 2025US 2025/0057900 A1Boehringer Ingelheim International GmbH
- Chimeric pseudotyped recombinant rabies virus3 Oct 2024US 2024/0327802 A1Beam Therapeutics Inc.
Most cited
By later US patents
- Methods for making modified recombinant vesiculoviruses51US 6,168,943 AYale University · 2001
- Recombinant vesiculoviruses and their uses39US 7,153,510 B1Yale University · 2006
- Apparatus for releasably holding a socket11US 11,091,778 B22021
- Coronavirus disease (COVID-19) vaccine2US 11,478,543 B1Thomas Jefferson University · 2022
- Multivalent vaccines for rabies virus and coronaviruses1US 11,041,170 B2The United States of America as represented by the Secretary, Department of Health and Human Service · 2021